I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
[Updated and corrected 8/27/15, 7:28pm, see below.] The new race to fight cholesterol is on. For the second time in a month, the U.S. Food and Drug Administration has... Read more »
The West Coast, according to the self-aggrandizing myth, is a place of re-invention, non-conformism, un-convention. You see this box, man? Our brains are over here, thinking outside of it. It’s all... Read more »
Like countless biotech companies with platform technologies that have preceded it, Seattle’s Adaptive Biotechnologies aims to be a drug company.
Adaptive has made a name for itself by sequencing the cells... Read more »
Before the arrival of the summer doldrums, Global Blood Therapeutics managed to go public, although “managed” probably isn’t the right word for a debut that beat pre-IPO targets and then doubled... Read more »
[Updated with first-day trading information, 1pm, 8/12/15.] The biotech bull run rolls on. Halfway through its first day of trading Wednesday, Global Blood Therapeutics has nearly doubled its share... Read more »
The high cost of cancer treatments is a huge topic of conversation these days. One way to trim those costs is to not give treatments to people who don’t need them.... Read more »
After a week off, the roundup is back. Up in Seattle, comments that the president of the Fred Hutchinson Cancer Research Center made a month ago raised some fresh hackles. In... Read more »
[Updated, 7/27/15, 7:35pm. See below.] After a battle with Alzheimer’s disease, audio engineering pioneer Ray Dolby died in 2013. Now his family is using the fortune he left behind... Read more »
The FDA has approved alirocumab (Praluent), a drug that gives people who aren’t helped enough by statins a new option to lower their cholesterol and fight heart disease. How many people... Read more »
[Corrected 7/27/15, 1.49pm. See below.] Spun out of its namesake two years ago, vaccine maker SutroVax has reeled in a $22 million Series A round to push forward a... Read more »
Biotechs everywhere are going public these days. You might have heard.
Approaching the traditional market lull in August, we’re up to nearly 40 life science IPOs in 2015, by my own... Read more »
Once again, the big West Coast news of the week came from an East Coast company, Celgene, making it rain. (That’s a figure of speech, unfortunately. Out here, rain would be... Read more »
Protagonist Therapeutics thinks it has solved a biological riddle, and several investors are shelling out $40 million to help test the company’s solution in humans for the first time before the... Read more »
They employ doctors, prescribe tests, and for $2,000 a year they’ll help you keep on top of your health, but they don’t diagnose illnesses. That’s the line new Seattle health startup... Read more »
The U.S. House of Representatives took a big step this morning toward major changes in the federal government’s relationship to biomedical research, funding, and regulation. The chamber passed the 21st Century... Read more »
Juno Therapeutics has built remarkable momentum—including last week’s much-dissected $1 billion deal with Celgene—upon early success treating leukemia and lymphoma patients with a first generation of experimental T cell therapies developed... Read more »
With an important clinical trial underway, South San Francisco, CA-based Global Blood Therapeutics hopes to join the ranks of public biotech companies. It has filed for an IPO worth as much... Read more »
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.